- 1) Established diagnosis of non-CF diabetes (i.e. T1D) or CFRD with fasting hyperglycemia, (fasting glucose > 126 mg/dL) 2) history of clinically symptomatic pancreatitis within last year, 3) prior lung or liver transplant, 4) severe CF liver disease, as defined by portal hypertension, 5) fundoplication-related dumping syndrome, 6) medical co-morbidities that are not CF-related or are unstable per investigator opinion (i.e. history of bleeding disorders, immunodeficiency), 7) acute illness or changes in therapy (including antibiotics) within 6 weeks prior to enrollment, 8) treatment with oral or intravenous corticosteroids within 6 weeks of enrollment, 9) hemoglobin <10g/dL, within 90 days of Visit 1 or at Screening, 10) abnormal renal function, within 90 days of Visit 1 or at Screening; defined as Creatinine clearance < 50 mL/min (based on the Cockcroft-Gault formula) or potassium > 5.5mEq/L on non-hemolyzed specimen, 11) a history of anaphylaxis, angioedema or Stevens-Johnson syndrome, 12) Inability to perform study specific procedures (MMTT, GPA), 13) Subjects, who in study team opinion, may be non-compliant with study procedures.